EcoDrugPlus

Bradykinin Receptor B2

Ensembl ID : ENSSTUG00000050261
Gene Symbol: BDKRB2
1 Cross references
149 Possible Orthologues:

Bradykinin Receptor B2

Ensembl ID : ENSSTUG00000016790
Gene Symbol: BDKRB2
3 Cross references
281 Possible Orthologues:

Bradykinin Receptor B2

Ensembl ID : ENSSTUG00000039798
Gene Symbol: BDKRB2
1 Cross references
148 Possible Orthologues:

Breakpoint Cluster Region Protein-Like

Ensembl ID : ENSSTUG00000020165
Gene Symbol: LOC115164669
3 Cross references
190 Possible Orthologues:

Breakpoint Cluster Region Protein-Like

Ensembl ID : ENSSTUG00000007965
Gene Symbol: LOC115199963
3 Cross references
190 Possible Orthologues:

Camp And Camp-Inhibited Cgmp 3',5'-Cyclic Phosphodiesterase 10a-Like

Ensembl ID : ENSSTUG00000049366
Gene Symbol: LOC115201744
3 Cross references
200 Possible Orthologues:

Camp-Specific 3',5'-Cyclic Phosphodiesterase 4c-Like

Ensembl ID : ENSSTUG00000023130
Gene Symbol: LOC115178581
2 Cross references
195 Possible Orthologues:

Camp-Specific 3',5'-Cyclic Phosphodiesterase 4d-Like

Ensembl ID : ENSSTUG00000048246
Gene Symbol: LOC115203776
2 Cross references
214 Possible Orthologues:

Cgmp-Specific 3',5'-Cyclic Phosphodiesterase-Like

Ensembl ID : ENSSTUG00000005963
Gene Symbol: LOC115199218
3 Cross references
217 Possible Orthologues:

Calcitonin Receptor Like Receptor

Ensembl ID : ENSSTUG00000041366
Gene Symbol: CALCRL
3 Cross references
141 Possible Orthologues:

Calcitonin Receptor Like Receptor

Ensembl ID : ENSSTUG00000048270
Gene Symbol: CALCRL
3 Cross references
141 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1d Subunit, A

Ensembl ID : ENSSTUG00000022566
Gene Symbol: CACNA1DA
1 Cross references
206 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).